Ensysce Biosciences is committed to finding a solution to the opioid crisis plaguing the US and other developed countries around the world. Through its proprietary TAAP technology Ensysce is in the process of receiving approval for an abuse-resistant yet still pain-relieving opioid. The company announced that it has initiated its pivotal Phase 3 study of PF614. This study aims to confirm that PF614 provided powerful pain relief, while being abuse resistant at the same time.